ArticleNature communications2022
A G358S mutation in the Plasmodium falciparum Na
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- Dual plasmepsin IX and X inhibitors are refractory to development of resistance.PLoS pathogens · 2026Article
- From Hit to Lead: Systematic Optimization of the Quinazolinedione Scaffold as Potent and Noncytotoxic Antimalarial Agents.ACS omega · 2026Article
- Addressing infectious diseases in Africa by accelerating drug discovery through data science.Communications medicine · 2025Review
- Endogenous structure of antimalarial target PfATP4 reveals an apicomplexan-specific P-type ATPase modulator.Nature communications · 2025Article
- Identification of α-Azacyclic Acetamide-Based Inhibitors ofACS infectious diseases · 2025Article
- PfATP2 is a flippase on the Plasmodium falciparum surface that is important for growth and influences parasite sensitivity to antiplasmodial compounds.PLoS pathogens · 2025Article
- Novel Inhibitors ofJournal of medicinal chemistry · 2025Article
- Article
- Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4.Journal of medicinal chemistry · 2025Article
- Gefitinib as an antimalarial: unveiling its therapeutic potential.Inflammopharmacology · 2025Article
- Towards next-generation treatment options to combat Plasmodium falciparum malaria.Nature reviews. Microbiology · 2025Review
- Lactam Truncation Yields a Dihydroquinazolinone Scaffold with Potent Antimalarial Activity that Targets PfATP4.ChemMedChem · 2024Article
- Open Source Code Contributions to Global Health: The Case of Antimalarial Drug Discovery.ACS medicinal chemistry letters · 2024Article
- The emergence of artemisinin partial resistance in Africa: how do we respond?The Lancet. Infectious diseases · 2024Review
- Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4.Journal of medicinal chemistry · 2024Article
- Enhancing the Intrinsic Antiplasmodial Activity and Improving the Stability and Selectivity of a Tunable Peptide Scaffold Derived from Human Platelet Factor 4.ACS infectious diseases · 2024Article
- Transmission-Blocking Strategies for Malaria Eradication: Recent Advances in Small-Molecule Drug Development.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Fungal Plasma Membrane HJournal of fungi (Basel, Switzerland) · 2024Review
- Genetic complexity alters drug susceptibility of asexual and gametocyte stages ofAntimicrobial agents and chemotherapy · 2024Article
- Detection of Developmental Asexual Stage-Specific RNA Editing Events inMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 8 institutions in 4 countries.
Deyun Qiu *Research School of Biology, Australian National University, Canberra, ACT, 2600, Australia.ORCID 0000-0002-7297-8660
Jinxin V Pei *Research School of Biology, Australian National University, Canberra, ACT, 2600, Australia.
James E O Rosling *Research School of Biology, Australian National University, Canberra, ACT, 2600, Australia.
Vandana ThathyDepartment of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Dongdi LiResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.
Yi XueResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.
John D TannerResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.ORCID 0000-0003-3914-3116
Jocelyn Sietsma PeningtonBioinformatic Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.ORCID 0000-0003-1561-0074
Yi Tong Vincent AwResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.
Jessica Yi Han AwResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.
Guoyue XuDepartment of Molecular Microbiology & Immunology and Johns Hopkins Malaria Institute, Johns Hopkins School of Public Health, Baltimore, MD, 21205, USA.ORCID 0000-0002-7699-8837
Abhai K TripathiDepartment of Molecular Microbiology & Immunology and Johns Hopkins Malaria Institute, Johns Hopkins School of Public Health, Baltimore, MD, 21205, USA.ORCID 0000-0001-9848-0142
Nina F GnadigDepartment of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Tomas YeoDepartment of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.ORCID 0000-0003-2923-6060
Kate J FairhurstDepartment of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Barbara H StokesDepartment of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.ORCID 0000-0001-9519-487X
James M MurithiDepartment of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Krittikorn KümpornsinWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Heath HasemerResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.
Adelaide S M DennisResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.
Melanie C RidgwayResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.ORCID 0000-0002-6763-2366
Esther K SchmittNovartis Pharma AG, Novartis Campus, Basel, 4056, Switzerland.
Judith StraimerNovartis Institute for Tropical Diseases, Emeryville, CA, 94608, USA.
Anthony T PapenfussBioinformatic Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.ORCID 0000-0002-1102-8506
Marcus C S LeeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.ORCID 0000-0002-4973-0915
Ben CorryResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.ORCID 0000-0002-6324-442X
Photini SinnisDepartment of Molecular Microbiology & Immunology and Johns Hopkins Malaria Institute, Johns Hopkins School of Public Health, Baltimore, MD, 21205, USA.ORCID 0000-0003-2954-7547
David A FidockDepartment of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.ORCID 0000-0001-6753-8938
Giel G van DoorenResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.ORCID 0000-0003-2455-9821
Kiaran KirkResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia.
Adele M LehaneResearch School of Biology, Australian National University, Canberra, ACT, 2600, Australia. adele.lehane@anu.edu.au.ORCID 0000-0002-0050-9101
Australian National University · AUColumbia University Irving Medical Center · USJohns Hopkins University · USWellcome Sanger Institute · GBNovartis (Switzerland) · CHNovartis (United States) · USThe University of Melbourne · AUWalter and Eliza Hall Institute of Medical Research · AU
Funding
The Skin Phase of Malaria Infection (Sharon Patray Diversity Supplement)R01AI132359 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SINNIS, PHOTINI · 2017 to 2021
$2.7MNIAID NIH HHS R01 AI132359Wellcome TrustWellcome Trust 206194/Z/17/Z
Abstract
Diverse compounds target the Plasmodium falciparum Na
Indexed as
AntimalarialsMalaria, FalciparumCalcium-Transporting ATPasesErythrocytesHumansIndolesIonsMutationPlasmodium falciparumSodiumSpiro CompoundsAntimalarialsCalcium-Transporting ATPasesIndolesIonsNITD 609SodiumSpiro Compounds
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.